Marilyn C. Pike

Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

Michael Simons, Brian H. Annex, Roger J. Laham et al. · Circulation · 2002 · 647 citations

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Daniel J. Wallace, Kenneth Kalunian, Michelle Petri et al. · Annals of the Rheumatic Diseases · 2013 · 323 citations · Full text

Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure

Raimund Hirschberg, Joel D. Kopple, Pamela Lipsett et al. · Kidney International · 1999 · 304 citations

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 223 citations · Full text

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

Roger J. Laham, Nicholas Chronos, Marilyn C. Pike et al. · Journal of the American College of Cardiology · 2000 · 222 citations

Heart Failure, Fibrosis, Health Sciences +11